Inhibiton Therapeutics Provides Update For ICA-1 Compound In-Vitro Testing In Breast Cancer Cell Lines

Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced that its ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. The present work performed under a Co-operative Research and Development Agreement (CRADA) with the Department of Veteran’s Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.

More: continued here

Filed under: Breast Cancer on January 29th, 2008